Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | HRAS | P01112 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13674556 | 0.92 | SLC6A9 (0.41) | SLC6A9ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL4515543 | 0.92 | SLC6A9 (0.41) | SLC6A9ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL13675466 | 0.84 | NPC1 (0.41) | SMN1; SMN2FFAR4 | |
| SCHEMBL13675470 | 0.82 | FFAR4 (0.36) | ALDH1A1HTR1AHSD11B1FFAR4 | |
| SCHEMBL13675463 | 0.79 | HSD11B1 (0.37) | HSD11B1FFAR4 | |
| SCHEMBL4501678 | 0.78 | FFAR4 (0.36) | ALDH1A1LMNAMEN1KMT2AHSD11B1 | |
| SCHEMBL13675515 | 0.78 | MAPT (0.41) | SMN1; SMN2MEN1KMT2AHSD11B1FFAR4 | |
| SCHEMBL4511934 | 0.78 | CXCR3 (0.40) | SMN1; SMN2 | |
| SCHEMBL13674553 | 0.78 | CXCR3 (0.40) | SMN1; SMN2 | |
| SCHEMBL4516252 | 0.76 | HSD11B1 (0.55) | LMNAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | SLC6A9 1638/4885ALDH1A1 51/4885HTT 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.